FILING ANALYSIS · THURSDAY, NOVEMBER 12
Kardigan, Inc. KARD — 8-K: Results of Operations and Financial Condition
neutral
Kardigan reported completion of enrollment in Phase 2b trials for danicamtiv and ataciguat, with topline data expected in 2Q 2027 and 2H 2027, respectively, and a cash position of $591.4 million to support multiple data readouts through 2027
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →